Area of research
Reproductive Medicine · Oncology
Research interest
Research interests include Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, HER2/EGFR in Cancer Research, and CAR-T cell therapy research.
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort.
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
MIRASOL: A randomized, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression (297)
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?
Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies
Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study
Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Uterine Neoplasms, Version 1.2014
Ovarian Cancer, Version 2.2013
Ovarian Cancer, Version 3.2012
Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours